KARPAS 707H Human Myeloma cell line

Technology No.

KARPAS 707H Human myeloma cell line suitable for the generation of stable human hybridomas for the creation of fully human monoclonal antibodies.

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio.

Internal Research Licence - 1 Year
1-year non-exclusive licence agreement for use of the Karpas 707H Cell Line for internal research only.

Term: 12 months

Price on approval

Sign up to our newsletter

If you would like to keep up to date with the latest opportunities, please sign up to our newsletter.